Patent based on the international application PCT/ES2009/070561, titled "Alpha-derivatives of cis-monounsaturated fatty acids intended for use as a drug". It is currently undergoing national phases in all major markets. The priority Spanish patent was granted in Spain last May 25th, 2011 (ES2342997) and has now also been granted in most major markets, including Europe (2374453), China (200980156029.6), Russia (2531353), Mexico (312101), Japan (5711140) South Korea (10-1683643), Australia (2009326993) or the USA (9000042). Different divisional/continuation applications are currently being pursued in all major markets in order to strengthen the protection for the key products and indications included in this patent family.
This patent is owned by the University of the Balearic Islands and Lipopharma has in-licensed exclusive worldwide rights. This is the main patent family protecting the current development in cancer with Minerval and it provides strong market protection until December 2029, with an additional 5 years extension possible in most territories.